Preface
Advances in theranostic biomarkers for lung cancer from clinical to molecular pathology
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S1-S2
.
(25 January 2019)
Review Article
Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S3-S8
.
(25 January 2019)
Mesenchymal tumors of the lung: diagnostic pathology, molecular pathogenesis, and identified biomarkers
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S9-S24
.
(25 January 2019)
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S25-S36
.
(25 January 2019)
Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S37-S44
.
(25 January 2019)
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S45-S56
.
(25 January 2019)
The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S57-S64
.
(25 January 2019)
Resistances to EGFR tyrosine kinase inhibitors in lung cancer— how to routinely track them in a molecular pathology laboratory?
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S65-S70
.
(25 January 2019)
Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S71-S80
.
(25 January 2019)
Update on emerging biomarkers in lung cancer
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S81-S88
.
(25 January 2019)
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S89-S101
.
(25 January 2019)
Are there any theranostic biomarkers in small cell lung carcinoma?
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S102-S112
.
(25 January 2019)
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Journal of Thoracic Disease
2019;
11
(Suppl 1)
:S113-S126
.
(25 January 2019)
Disclosure:
The supplement “Advances in Theranostic Biomarkers for Lung Cancer: from Clinical to Molecular Pathology” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Paul Hofman served as the unpaid Guest Editor for the supplement.
